AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
VANCOUVER, B.C. -- Evidence of the teratogenic effects of many older generation anticonvulsants is strong, but data on the newer generation drugs remain inconclusive, Dr. Lewis B. Holmes said at the annual meeting of the Teratology Society.
Anticonvulsants represent one of the most common potential teratogenic drug exposures. Cohort and case studies show that older drugs such as carbamazepine, phenytoin, phenobarbital, and valproate can have effects ranging from major malformations and midface and digit hypoplasia to growth restriction and cognitive dysfunction.
While data on the teratogenic effects of newer anticonvulsants are strong, few research efforts offer an ideal cohort study with a well-assembled comparison group, said Dr. Holmes of Massachusetts General Hospital in Boston.
Small studies that have generated some insight into the new generation of anticonvulsants have focused on lamotrigine (804 pregnancies): clonazepam (70 pregnancies); and gabapentin (48 pregnancies), however, none of the studies has been large enough to offer definitive results, according to Dr. Holmes.
The most promising hope for obtaining enough patients for a sound study lies in pregnancy registries, Dr. Holmes said.
Registries to report anticonvulsant drug use in pregnancy have been developed in North America, Australia, and the United Kingdom, as well as in 37 countries participating in the European ...
Source: HighBeam Research, Effects in pregnancy: better data needed on newer...